Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. (NASDAQ: ANIX) is a clinical-stage biotechnology company dedicated to the treatment and prevention of cancer. The company's core focus includes developing vaccines and therapies aimed at critical unmet needs in oncology. Anixa's innovative approach involves both diagnostics and therapeutics to detect and treat cancer at its most curable stages.
The company's therapeutic portfolio features a pioneering ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center. This program utilizes a novel CAR-T technology, known as chimeric endocrine receptor T-cell (CER-T), which targets the follicle-stimulating hormone receptor (FSHR) specifically expressed on ovarian cells. This technology represents a potential breakthrough in treating solid tumors, a challenge for traditional CAR-T therapies.
Anixa is also advancing a unique vaccine portfolio in collaboration with Cleveland Clinic, targeting the prevention of breast cancer, specifically triple-negative breast cancer (TNBC), the most aggressive form of the disease, as well as ovarian cancer. These vaccine technologies focus on immunizing against
Anixa Biosciences (NASDAQ: ANIX) and Moffitt Cancer Center have received approval for a protocol amendment in their ongoing ovarian cancer CAR-T therapy clinical trial. The amendment brings two significant changes: it allows eligible patients to receive a second dose of CAR-T therapy without requiring individual IND approvals, and expands enrollment eligibility to include patients with sex cord-stromal tumors (SCSTs) and Sertoli Leydig cell tumors (SLCTs).
Previously, Anixa and Moffitt had secured a single patient IND approval for an additional dose for a patient whose biopsy showed cellular infiltration and necrosis, indicating biological activity of the CAR-T therapy. The amendment aims to optimize treatment outcomes for patients with ovarian cancer by providing more flexibility in dosing and expanding the types of ovarian cancers that can be treated.
Anixa Biosciences (NASDAQ: ANIX) CEO Dr. Amit Kumar discussed the company's innovative cancer treatments in an Alpha Wolf Trading interview. The company is developing two main programs: a CAR-T cell therapy for ovarian cancer and a breast cancer vaccine.
The CAR-T therapy aims to overcome challenges in treating solid tumors, distinguishing it from traditional approaches that work primarily on blood cancers. The breast cancer vaccine targets triple-negative breast cancer (TNBC), the most aggressive form of the disease.
The company emphasizes its capital-efficient business model, maintaining a low burn rate through strategic partnerships with research institutions. This approach reduces the need for extensive in-house R&D expenditures while advancing their therapeutic developments.
Anixa Biosciences (NASDAQ: ANIX) has announced its participation in the 18th Annual European Life Sciences CEO Forum, scheduled for February 26-27, 2025, at the Hilton Zurich Airport Hotel in Switzerland. Mike Catelani, President and CFO, will present on February 27 at 10:40 AM CET.
The presentation will focus on Anixa's pipeline updates, including their:
- CAR-T therapy for ovarian cancer (collaboration with Moffitt Cancer Center)
- Breast cancer vaccine (partnership with Cleveland Clinic)
- Expanding portfolio of cancer vaccine programs
The conference brings together key executives, investors, and industry experts from the global life sciences sector to discuss innovations, investment trends, and partnership opportunities. Mr. Catelani will also conduct one-on-one meetings with potential partners and investors to discuss strategic initiatives and clinical advancements in their innovative therapies.
Anixa Biosciences (NASDAQ: ANIX) CEO Dr. Amit Kumar appeared on CW39's H-Town Live to discuss the company's innovative approach to breast cancer prevention. The segment highlighted Anixa's collaboration with the Cleveland Clinic in developing a novel vaccine targeting triple-negative breast cancer (TNBC), the most aggressive form of the disease.
The vaccine, currently in clinical trials, is designed to target a specific protein present in TNBC cells but absent in normal breast tissue. The goal is to stimulate the immune system to eliminate cancer cells before they develop into tumors, potentially eliminating the need for traditional treatments like chemotherapy and surgery.
Anixa Biosciences (NASDAQ: ANIX) reported significant progress in 2024, maintaining strong financials with $20 million in cash and investments after using only $7 million during the fiscal year. The company presented positive preliminary Phase 1 data for their breast cancer vaccine at SITC, showing protocol-defined immune responses in over 70% of patients across three groups: recurrence, prevention, and therapeutic.
Their CAR-T program for ovarian cancer progressed through the second dose cohort and began the third, with one patient from the first cohort showing strong response and surviving 21+ months post-treatment. The company expanded their vaccine development to include prostate, lung, and colon cancers.
For 2025, Anixa plans to complete the breast cancer vaccine Phase 1 trial and initiate Phase 2, complete treatment of third through fifth dose cohorts in the CAR-T trial, and continue developing vaccines for multiple cancer types. With a 2.5-year cash runway and debt-free structure, the company is positioned to execute its development plans.
Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced its participation in the iAccess Alpha Virtual Best Ideas Winter Conference 2024. The event will take place on December 10th and 11th, 2024.
Dr. Amit Kumar, CEO of Anixa, will deliver a presentation on Tuesday, December 10th at 2:00 p.m. EST. The company's management team will be available for one-on-one meetings with qualified investors on Wednesday, December 11th.
The conference, hosted by iAccess Alpha, features companies recommended by an investor network and follows a two-day format with company webcasts on the first day and one-on-one management meetings on the second day.
Anixa Biosciences (NASDAQ: ANIX) announced its Board of Directors has approved the purchase of Bitcoin as a treasury reserve asset. The company aims to diversify holdings while maintaining its ongoing stock buyback program. Management highlighted positive results from their breast cancer vaccine and ovarian cancer therapy clinical trials, emphasizing low cash burn rates. The decision to invest in Bitcoin is presented as part of their financial management strategy, with the company citing Bitcoin's growing recognition as a mainstream asset class, inflation-resistant qualities, and the recent approval of Bitcoin ETFs as supporting factors.
Anixa Biosciences (NASDAQ: ANIX) has initiated dosing in the third cohort of its Phase 1 ovarian cancer CAR-T clinical trial, conducted in partnership with Moffitt Cancer Center. The new cohort receives one million CAR-positive cells, a tenfold increase from the initial dose. No dose-limiting toxicity was observed in the first two cohorts. The trial targets the follicle-stimulating hormone receptor (FSHR) in patients with recurrent ovarian cancer who have progressed on at least two prior therapies. Notably, one patient from the first cohort showed unusual stability and mild improvement for over a year post-infusion, with tumor biopsy revealing necrosis and T cell infiltration.
Anixa Biosciences and Cleveland Clinic presented updated positive data from their Phase 1 breast cancer vaccine trial at the SITC Annual Meeting. The vaccine, targeting α-lactalbumin protein, showed safety and tolerability across all three cohorts, with over 70% of patients exhibiting protocol-defined immune responses. The trial includes patients who completed triple-negative breast cancer treatment, high-risk individuals with genetic mutations, and patients receiving Keytruda. The primary side effect was injection site irritation. Based on these positive results, a Phase 2 study is planned for 2025, focusing on newly diagnosed breast cancer patients in the neoadjuvant setting.
Anixa Biosciences (NASDAQ: ANIX) announced that additional data from the Phase 1 clinical trial of its breast cancer vaccine will be made public on November 8, 2024, at 12:15pm CT. The presentation, titled 'Phase I Trial of alpha-lactalbumin vaccine in high risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC,' will be presented at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The data will be available on the company's website, accompanied by a press release analyzing the results.
FAQ
What is the current stock price of Anixa Biosciences (ANIX)?
What is the market cap of Anixa Biosciences (ANIX)?
What does Anixa Biosciences specialize in?
What are the key components of Anixa's therapeutic portfolio?
What recent achievements has Anixa Biosciences announced?
Who are some of Anixa Biosciences' key collaborators?
How does Anixa's CER-T technology differ from traditional CAR-T therapies?
What is unique about Anixa's cancer vaccine technology?
Which forms of cancer are Anixa's vaccines targeting?
What are some recent clinical trial results from Anixa?
Does Anixa Biosciences participate in industry conferences?
Where can I find more information about Anixa Biosciences?
